Home > Healthcare & Medical Devices > Aquaculture Vaccines Market

Aquaculture Vaccines Market Size By Type of Vaccines (Inactivated Vaccines, Live Vaccines), By Route of Administration (Immersion Vaccines, Injection Vaccines, Oral Vaccines), By Application (Bacterial Infection, Viral Infection), By Species (Salmon, Trout, Tilapia), COVID-19 Impact Analysis, Industry Analysis Report, Regional Outlook, Growth Potential, Competitive Market Share & Forecast, 2023 – 2032

  • Report ID: GMI3323
  • Published Date: Dec 2022
  • Report Format: PDF

Industry Statistics

Aquaculture Vaccines Market size crossed USD 214.5 million in 2022 and is projected to expand at over 7.5% CAGR from 2023-2032.

Get more details on this report - Request Free Sample PDF

Increasing prevalence of viral and bacterial infections is expected to fuel the need for aquaculture vaccines over the projected timeframe. The risk of mixed bacterial-viral infections and lone bacterial infections is a major challenge in fish production caused by changes in the aquatic ecosystem. Bacteria and viruses account for more than 50% of the infectious diseases that invade and disrupt aquaculture production. Increasing awareness regarding fish quality and health increases the need for appropriate conditions for fish production.

Strict regulatory policies for vaccine approval to hamper industry progress

Stringent regulatory frameworks pertaining to vaccine approvals may impede the development and commercialization of aquaculture vaccines. Multiple governments and public bodies have deployed guidelines to ensure the safe and effective employment of vaccines designed for fish farming. Additionally, manufacturers are rapidly adopting In Process Quality Control (IPQC), and Good Manufacturing Practices (GMPs). Vaccine approval procedures regulated by the U.S. FDA and European Union are time-consuming and restrain new market entrants. Very strict impact surveillance and pharmacovigilance of vaccines are adhered to before any vaccine is approved for aquacultural use.

Technological advancements in inactivated aquaculture vaccines to complement industry outlook

Get more details on this report - Request Free Sample PDF

Aquaculture vaccines market from inactivated vaccines segment was valued at more than USD 173.5 million in 2022.  Technological advancements along with growing demand for effective solutions in fish farming to accelerate the immune system will pave the way for inactivated vaccines. This type of vaccine is vital in the aquaculture sector as it helps induce strong immune responses by retaining the immobilized genomic components. It also helps protect antigens that are exposed to virus surfaces, ultimately strengthening immunity. Inactivated vaccines offer multiple benefits including cost-effectiveness and are non-reactive under field conditions.

Growing need for anti-infectives in aquaculture farming to boost demand for injection vaccine deliveries

Aquaculture vaccines market size from injection vaccines is projected to record over 7% CAGR between 2023-2032. The most common route of administration in fish is injecting the vaccines, enabling highly efficient and productive aquaculture farming by mitigating the spread of bacterial and viral diseases. Vaccine delivery via injection helps directly target the body cavity or muscle, allowing direct activation of the systematic immune response. Injection vaccines are relatively more effective in treating several infectious diseases than other routes of administration. These vaccines consist of water-based or oil-based substances called adjuvants which are the primary stimulators of the immune response.

Rising incidences of infectious pancreatic necrosis viruses to propel preference for aquaculture vaccines

Aquaculture vaccines market share from viral infections is estimated to reach over USD 72 million by the end of 2032. Viral infections are one of the biggest roadblocks for fish farmers and aquaculture producers, thus driving the demand for efficient and affordable management of infectious diseases. Salmon anemia virus, hematopoietic necrosis virus, koi herpes, epizootic hematopoietic necrosis virus, viral hemorrhagic septicemia virus, and pancreatic necrosis virus are some of the leading causes of infectious diseases in aquaculture farming.

Surging tilapia production to mitigate disease outbreaks to accelerate demand for aquaculture vaccines

Get more details on this report - Request Free Sample PDF

Aquaculture vaccines market from tilapia species segment valuation is anticipated to exceed USD 74.5 million by 2032. Surging demand for tilapia and increasing economic significance will proliferate the need for aquaculture vaccines in tilapia production. This fish is the second-most predominant species, effectively reaching harvest size within 6-7 months, and is widely consumed by people worldwide. For instance, according to the Food & Agriculture Organization (FAO), in 2019-2020, tilapia accounted for more than 4% of global aquaculture production, emerging as the fifth most crucial finfish species. Increasing need for disease outbreak prevention and management in tilapia species will positively affect the industry outlook.

Large-scale fish farming activities to fuel Europe market expansion

Europe aquaculture vaccines market size is expected to surpass USD 203.5 million by 2032. Europe is anticipated to emerge as a key hotspot for aquaculture vaccine manufacturers owing to the increasing number of fish farming activities. Extensive R&D initiatives and ongoing innovation in the field of new vaccines and biologics will further consolidate industry expansion across the region. Favorable government regulations promoting the use of antibiotics will also offer lucrative business prospects. Additionally, the surging production of trout, salmon and other varieties of fish species due to the high consumption of seafood in the region will accelerate the need for vaccines to ensure food quality.

Get more details on this report - Request Free Sample PDF

Mergers & acquisitions to foster the competitive landscape

Some of the leading companies in the aquaculture vaccines market include Zoetis Inc., Merck & Co., Inc., HIPRA, Tecnovax, Virbac, Veterquimica S.A, Nisseiken Co. Ltd., Phibro Animal Health Corporation, Vaxxinova International BV, Kyoto Biken Laboratories, Inc. These companies are focusing on strategic alliances, mergers, and acquisitions to consolidate competitive lead. For instance, in July 2020, Zoetis announced the acquisition of Fish Vet Group from Benchmark Holdings, Plc to expand the company’s geographic footprint and boost diagnostic capabilities.

Impact of COVID-19 pandemic on the aquaculture vaccines market development

The emergence of the COVID-19 pandemic in 2020 had a negative impact on aquaculture vaccine production worldwide. A dramatic rise in the spread of infection and pandemic-related morbidity and mortality along with significant supply chain disruptions hampered the overall business performance. Due to lockdown restrictions and social distancing norms, the production of aquaculture vaccines was hindered by a dearth of the workforce and increasing focus on manufacturing COVID-19 vaccines.

The aquaculture vaccines market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD million from 2018 to 2032, for the following segments:

By Type of Vaccine

  • Inactivated vaccine
  • Live vaccine
  • Others

By Route of Administration

  • Immersion vaccines
  • Injection vaccines
  • Oral vaccines

By Application

  • Bacterial infection
  • Viral infection
  • Others

By Species

  • Salmon
  • Trout
  • Tilapia
  • Others

The above information is provided for the following regions and countries:

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Spain
    • Italy
    • Norway
    • Ireland
    • Turkey
    • Denmark
  • Asia Pacific
    • China
    • Indonesia
    • Philippines
    • Thailand
    • Australia
    • New Zealand
  • Latin America
    • Brazil
    • Mexico
    • Chile
  • Middle East and Africa
    • Iran
    • Egypt


Authors: Sumant Ugalmugle, Rupali Swain

Frequently Asked Questions (FAQ) :

Global market for aquaculture vaccines reached over USD 214.5 million in 2022 and is projected to expand at over 7.5% CAGR from 2023-2032.
Viral infections is estimated to reach over USD 72 million by the end of 2032 due to growing incidences of infectious pancreatic necrosis virus.
Europe aquaculture vaccines market size is expected to surpass USD 203.5 million by 2032 driven by an increasing number of fish farming initiatives and R&D activities.
Zoetis Inc., Merck & Co., Inc., HIPRA, Tecnovax, Virbac, Veterquimica S.A, and Nisseiken Co. Ltd. are some of the major manufacturers of aquaculture vaccines worldwide.

Buy Now

Premium Report Details

  • Base Year: 2022
  • Companies covered: 10
  • Tables & Figures: 278
  • Countries covered: 22
  • Pages: 170
  • Upcoming Report: Details can be customized to meet your information and data needs. Feel free to share your detailed research requirements via this form.

Get a report that explains COVID-19 impact on this market

 Request Free Sample

Budget constraints? Get in touch with us for special pricing

Request Discount